CL2015003444A1 - Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo - Google Patents

Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo

Info

Publication number
CL2015003444A1
CL2015003444A1 CL2015003444A CL2015003444A CL2015003444A1 CL 2015003444 A1 CL2015003444 A1 CL 2015003444A1 CL 2015003444 A CL2015003444 A CL 2015003444A CL 2015003444 A CL2015003444 A CL 2015003444A CL 2015003444 A1 CL2015003444 A1 CL 2015003444A1
Authority
CL
Chile
Prior art keywords
dihydroisoquinolin
compounds
treatment
ilo
schizophrenia
Prior art date
Application number
CL2015003444A
Other languages
English (en)
Inventor
David Andrew Coates
Christopher David Beadle
Junliang Hao
Jr Joseph Herman Krushinski
Mattheww Robert Reinhard
John Mehnert Schaus
Craig Daniel Wolfangel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2015003444A1 publication Critical patent/CL2015003444A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

COMPUESTOS DERIVADOS DE 3,4 DIHIDROISOQUINOLIN-2(1H)-ILO; COMPOSICION FARMACEUTICA; Y SU USO EN EL TRATAMIENTO DE LA ESQUIZOFRENIA Y EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON
CL2015003444A 2013-05-30 2015-11-24 Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo CL2015003444A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361828740P 2013-05-30 2013-05-30
US201361905329P 2013-11-18 2013-11-18

Publications (1)

Publication Number Publication Date
CL2015003444A1 true CL2015003444A1 (es) 2016-07-15

Family

ID=50983199

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003444A CL2015003444A1 (es) 2013-05-30 2015-11-24 Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo

Country Status (38)

Country Link
US (1) US8962654B2 (es)
EP (1) EP3004061B8 (es)
JP (2) JP6130590B2 (es)
KR (1) KR101808933B1 (es)
CN (1) CN105228985B (es)
AP (1) AP2015008867A0 (es)
AU (2) AU2014274435B2 (es)
BR (1) BR112015029090B1 (es)
CA (1) CA2912849C (es)
CL (1) CL2015003444A1 (es)
CR (1) CR20150622A (es)
CY (1) CY1119361T1 (es)
DK (1) DK3004061T3 (es)
DO (1) DOP2015000289A (es)
EA (1) EA029220B1 (es)
ES (1) ES2647086T3 (es)
GT (1) GT201500334A (es)
HK (1) HK1216314A1 (es)
HR (1) HRP20171696T1 (es)
HU (1) HUE034607T2 (es)
JO (1) JO3316B1 (es)
LT (1) LT3004061T (es)
ME (1) ME02838B (es)
MX (1) MX2015016495A (es)
MY (1) MY180751A (es)
NZ (1) NZ713809A (es)
PE (1) PE20152032A1 (es)
PH (1) PH12015502658A1 (es)
PL (1) PL3004061T3 (es)
PT (1) PT3004061T (es)
RS (1) RS56294B1 (es)
SG (1) SG11201509310QA (es)
SI (1) SI3004061T1 (es)
TN (1) TN2015000514A1 (es)
TW (2) TWI691489B (es)
UA (1) UA118759C2 (es)
WO (1) WO2014193781A1 (es)
ZA (1) ZA201508213B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3133070T (pt) 2009-11-27 2019-11-11 Genzyme Corp Eliglustat (genz 112638) como inibidor de glicosilceramida-sintase para utilização num método de tratamento de doença de fabry ou de gaucher, o método compreendendo ajustar a dose terapêutica individual ao metabolismo do p-450 do doente
JO3316B1 (ar) * 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
AR106332A1 (es) * 2015-10-23 2018-01-03 Lilly Co Eli Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona
JP6908623B2 (ja) * 2016-04-13 2021-07-28 ユーシービー バイオファルマ エスアールエル テトラヒドロイソキノリン誘導体
WO2018156595A1 (en) 2017-02-21 2018-08-30 Emory University Chemokine cxcr4 receptor modulators and uses related thereto
EP3418270A1 (en) 2017-06-19 2018-12-26 Universidad Complutense De Madrid Novel biphenylsulfoximines as allosteric modulators of the dopamine d1 receptor
MA51199A (fr) 2017-12-01 2020-10-07 UCB Biopharma SRL Agents d'imagerie
TWI725408B (zh) * 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑
AU2019402087B2 (en) 2018-12-18 2023-04-06 Eli Lilly And Company Dose regimens for use of LY3154207 in the treatment of dopaminergic CNS disorders
TWI825323B (zh) * 2019-06-18 2023-12-11 美商美國禮來大藥廠 用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物
CA3139571A1 (en) 2019-07-01 2021-01-07 UCB Biopharma SRL A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
MX2021015872A (es) 2019-07-01 2022-02-03 UCB Biopharma SRL Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1.
WO2022076418A1 (en) 2020-10-07 2022-04-14 Eli Lilly And Company Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1 receptor positive allosteric modulators
WO2022117678A1 (en) 2020-12-03 2022-06-09 UCB Biopharma SRL Octahydroisoquinolinyl derivatives
EP4263522A1 (en) * 2020-12-18 2023-10-25 UCB Biopharma SRL Dihydroisoquinolinyl derivatives
WO2022129356A1 (en) * 2020-12-18 2022-06-23 UCB Biopharma SRL Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]ethanone
IL303688A (en) * 2020-12-18 2023-08-01 UCB Biopharma SRL Amorphous solid dispersions
WO2022129268A1 (en) 2020-12-18 2022-06-23 UCB Biopharma SRL A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
EP4304581A1 (en) 2021-03-08 2024-01-17 Eli Lilly And Co. Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis
CN117337173A (zh) 2021-03-09 2024-01-02 伊莱利利公司 美维达林和其他d1正向别构调节剂用于减缓帕金森氏病进展的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68910999T2 (de) 1988-02-19 1994-03-24 Smithkline Beecham Farma 1,2,3,4-Tetrahydroisoquinoline, Verfharen zu ihrer Herstellung und ihre Verwendung als Kappa-Rezeptor Agonisten.
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
US5932590A (en) 1996-12-05 1999-08-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
ZA991301B (en) 1998-02-18 1999-09-13 Neurosearch As Glutamate receptor modulators.
ES2252230T3 (es) 2000-05-11 2006-05-16 Bristol-Myers Squibb Company Analogos de tetrahidroisoquinolina utiles como secretores de la hormona del crecimiento.
US7601739B2 (en) 2003-08-08 2009-10-13 Virgina Commonwealth University Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases
US7541466B2 (en) 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
KR20090127307A (ko) * 2007-03-01 2009-12-10 얀센 파마슈티카 엔.브이. 히스타민 ｈ３ 수용체 조절제로서의 테트라하이드로이소퀴놀린 화합물
US20120252853A1 (en) * 2011-04-01 2012-10-04 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
RU2014129613A (ru) 2011-12-21 2016-02-10 Актелион Фармасьютиклз Лтд Гетероциклильные производные и их применение в качестве модуляторов рецептора простагландина d2
JO3316B1 (ar) * 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل

Also Published As

Publication number Publication date
EP3004061B1 (en) 2017-08-30
PH12015502658B1 (en) 2016-03-07
AU2014274435A1 (en) 2015-11-19
CN105228985B (zh) 2017-05-10
KR101808933B1 (ko) 2017-12-13
TW201536745A (zh) 2015-10-01
SI3004061T1 (sl) 2017-10-30
NZ713809A (en) 2019-11-29
BR112015029090A2 (pt) 2017-07-25
AU2016238934A1 (en) 2016-10-27
JP2016520127A (ja) 2016-07-11
JO3316B1 (ar) 2019-03-13
US8962654B2 (en) 2015-02-24
CY1119361T1 (el) 2018-02-14
TW201940469A (zh) 2019-10-16
TN2015000514A1 (en) 2017-04-06
BR112015029090B1 (pt) 2023-05-09
AU2014274435B2 (en) 2016-07-14
PT3004061T (pt) 2017-10-19
AU2016238934B2 (en) 2017-08-03
JP6130590B2 (ja) 2017-05-17
HUE034607T2 (en) 2018-02-28
ZA201508213B (en) 2017-08-30
ME02838B (me) 2018-01-20
US20140357664A1 (en) 2014-12-04
EA029220B1 (ru) 2018-02-28
EP3004061B8 (en) 2017-10-04
PH12015502658A1 (en) 2016-03-07
TWI691489B (zh) 2020-04-21
DK3004061T3 (en) 2017-10-23
HK1216314A1 (zh) 2016-11-04
BR112015029090A8 (pt) 2020-03-17
TWI691488B (zh) 2020-04-21
SG11201509310QA (en) 2015-12-30
AP2015008867A0 (en) 2015-11-30
LT3004061T (lt) 2017-11-27
MX2015016495A (es) 2016-03-01
CR20150622A (es) 2016-01-06
MY180751A (en) 2020-12-08
WO2014193781A1 (en) 2014-12-04
PE20152032A1 (es) 2016-01-28
CN105228985A (zh) 2016-01-06
JP2017178945A (ja) 2017-10-05
EA201592082A1 (ru) 2016-04-29
ES2647086T3 (es) 2017-12-19
GT201500334A (es) 2018-11-23
PL3004061T3 (pl) 2018-01-31
UA118759C2 (uk) 2019-03-11
EP3004061A1 (en) 2016-04-13
CA2912849A1 (en) 2014-12-04
CA2912849C (en) 2017-05-30
JP6387433B2 (ja) 2018-09-05
DOP2015000289A (es) 2015-12-31
KR20160003110A (ko) 2016-01-08
HRP20171696T1 (hr) 2017-12-29
RS56294B1 (sr) 2017-12-29

Similar Documents

Publication Publication Date Title
CL2015003444A1 (es) Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo
CL2015001358A1 (es) Potenciadores del cftr deuterados
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
PH12019500176A1 (en) Heterocyclic compounds and ther uses
CL2016001895A1 (es) Compuestos
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2016001629A1 (es) Compuestos tricíclicos como agentes anticancerígenos
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2015001702A1 (es) Compuestos triciclicos antivirales; composicion farmaceutica; y uso en el tratamiento de la hepatitis c.
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
CL2015003686A1 (es) Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades
CL2013002125A1 (es) Compuestos derivados de imidazo[5,1-f][1,2,4]triazinas; composicion farmaceutica; y uso en el tratamiento del deterioro cognitivo asociado con esquizofrenia.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CL2014002412A1 (es) Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras.
SG10201804306VA (en) THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS
CL2014001858A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
UY33865A (es) Derivados Heterocíclicos Novedosos y su Uso en el Tratamiento de Trastornos Neurológicos
CL2015000784A1 (es) Compuestos derivados de acilaminopirimidina, inductores de interferon; composicion farmaceutica que los comprende; su uso en el tratamiento de infecciones viricas, trastornos inmunitarios, cancer y otras enfermedades.
CL2018001171A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
CL2015001342A1 (es) Compuestos derivados de pirrolo[3,2-d]pirimidina; composicion farmaceutica y de vacuna que los comprende y el uso en el tratamiento de enfermedades alergicas y otras enfermedades inflamatorias, infecciosas y cancer.